Exploiting human immune repertoire transgenic mice for protective monoclonal antibodies against antimicrobial resistant Acinetobacter baumannii.
Saved in:
| Title: | Exploiting human immune repertoire transgenic mice for protective monoclonal antibodies against antimicrobial resistant Acinetobacter baumannii. |
|---|---|
| Authors: | Baker S; University of Cambridge School of Clinical Medicine Cambridge Biomedical Campus, Cambridge, UK.; IAVI, Chelsea and Westminster Hospital, London, UK., Krishna A; Kymab, a Sanofi Company, Babraham Research Campus, Cambridge, UK., Higham S; Department of Infectious Disease, Imperial College London, St Marys Campus, Norfolk Place, London, UK., Naydenova P; University of Cambridge School of Clinical Medicine Cambridge Biomedical Campus, Cambridge, UK., O'Leary S; Kymab, a Sanofi Company, Babraham Research Campus, Cambridge, UK., Scott JB; Kymab, a Sanofi Company, Babraham Research Campus, Cambridge, UK., Harcourt K; University of Cambridge School of Clinical Medicine Cambridge Biomedical Campus, Cambridge, UK., Forrest S; University of Cambridge School of Clinical Medicine Cambridge Biomedical Campus, Cambridge, UK., Goulding D; Pathogens and Microbes Programme, Wellcome Sanger Institute, Cambridge, UK., Thi Nguyen TN; Department of Microbiology, Monash Biomedicine Discovery Institute, Monash University, Melbourne, Victoria, Australia., Toan ND; Neonatal Intensive Care Unit, Children's Hospital 1, Ho Chi Minh City, Vietnam., Alekseeva E; Kymab, a Sanofi Company, Babraham Research Campus, Cambridge, UK., Zhou Q; Kymab, a Sanofi Company, Babraham Research Campus, Cambridge, UK., Andreozzi I; Kymab, a Sanofi Company, Babraham Research Campus, Cambridge, UK., Sobotic B; Kymab, a Sanofi Company, Babraham Research Campus, Cambridge, UK., Craig H; Kymab, a Sanofi Company, Babraham Research Campus, Cambridge, UK., Wong V; Kymab, a Sanofi Company, Babraham Research Campus, Cambridge, UK., Forrest-Owen N; Kymab, a Sanofi Company, Babraham Research Campus, Cambridge, UK., Sanchez DM; Kymab, a Sanofi Company, Babraham Research Campus, Cambridge, UK., Pearce C; Kymab, a Sanofi Company, Babraham Research Campus, Cambridge, UK., Roberts L; European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Hinxton, UK., Watson S; Kymab, a Sanofi Company, Babraham Research Campus, Cambridge, UK., Clare S; University of Cambridge School of Clinical Medicine Cambridge Biomedical Campus, Cambridge, UK., Torok ME; University of Cambridge School of Clinical Medicine Cambridge Biomedical Campus, Cambridge, UK., Dougan G; University of Cambridge School of Clinical Medicine Cambridge Biomedical Campus, Cambridge, UK., Kellam P; Kymab, a Sanofi Company, Babraham Research Campus, Cambridge, UK.; Department of Infectious Disease, Imperial College London, St Marys Campus, Norfolk Place, London, UK., Tregoning JS; Department of Infectious Disease, Imperial College London, St Marys Campus, Norfolk Place, London, UK., Reece ST; Kymab, a Sanofi Company, Babraham Research Campus, Cambridge, UK. stephen.reece@sanofi.com. |
| Source: | Nature communications [Nat Commun] 2024 Sep 12; Vol. 15 (1), pp. 7979. Date of Electronic Publication: 2024 Sep 12. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2041-1723 |
|---|---|
| DOI: | 10.1038/s41467-024-52357-8 |
